Literature DB >> 8221197

Alterations in erythrocyte glutathione metabolism associated with cervical dysplasias and carcinoma in situ.

J Basu1, C Duttagupta, S H Vermund, C Ahn, P R Palan, S L Romney.   

Abstract

The study was designed to test the hypothesis whether cervical dysplasias of the more severe grades are associated with elevated erythrocyte glutathione levels. Subjects were women who obtained Pap tests and were subsequently found (1) not to have any cervical lesions or (2) to have colposcopically visualized, biopsy-confirmed cervical abnormalities histopathologically diagnosed as mild, moderate, severe dysplasias, or carcinoma in situ (CIS). The erythrocyte levels of reduced glutathione (GSH), oxidized glutathione (GSSG), glutathione reductase (GR), glucose-6-phosphate dehydrogenase (G6PD), and 6-phosphogluconate dehydrogenase (6PGD) were analyzed from coded peripheral venous blood samples. GSH and GR concentrations increased with increasing severity of dysplasia. Exploratory data analysis and multiple pairwise comparisons suggested comparable levels of the glutathione-related variables between these histopathological pairs: (1) mild and moderate dysplasias or (2) severe dysplasia and CIS. We suggest that the changes in erythrocyte glutathione-related indices in conjunction with histopathological diagnosis may have the potential to distinguish between low- and high-grade cervical dysplastic lesions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221197     DOI: 10.3109/07357909309046937

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  4 in total

1.  Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.

Authors:  Changliang Shan; Shannon Elf; Quanjiang Ji; Hee-Bum Kang; Lu Zhou; Taro Hitosugi; Lingtao Jin; Ruiting Lin; Liang Zhang; Jae Ho Seo; Jianxin Xie; Meghan Tucker; Ting-Lei Gu; Jessica Sudderth; Lei Jiang; Ralph J DeBerardinis; Shaoxiong Wu; Yuancheng Li; Hui Mao; Peng R Chen; Dongsheng Wang; Georgia Zhuo Chen; Sagar Lonial; Martha L Arellano; Hanna J Khoury; Fadlo R Khuri; Benjamin H Lee; Daniel J Brat; Keqiang Ye; Titus J Boggon; Chuan He; Sumin Kang; Jun Fan; Jing Chen
Journal:  Mol Cell       Date:  2014-07-17       Impact factor: 17.970

2.  Discovery of Ebselen as an Inhibitor of 6PGD for Suppressing Tumor Growth.

Authors:  Qi Feng; Xiuru Li; Wenjing Sun; Yubo Li; Yu Yuan; Baozhang Guan; Shuai Zhang
Journal:  Cancer Manag Res       Date:  2020-08-05       Impact factor: 3.989

Review 3.  6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.

Authors:  Ruiting Lin; Shannon Elf; Changliang Shan; Hee-Bum Kang; Quanjiang Ji; Lu Zhou; Taro Hitosugi; Liang Zhang; Shuai Zhang; Jae Ho Seo; Jianxin Xie; Meghan Tucker; Ting-Lei Gu; Jessica Sudderth; Lei Jiang; Matthew Mitsche; Ralph J DeBerardinis; Shaoxiong Wu; Yuancheng Li; Hui Mao; Peng R Chen; Dongsheng Wang; Georgia Zhuo Chen; Selwyn J Hurwitz; Sagar Lonial; Martha L Arellano; Hanna J Khoury; Fadlo R Khuri; Benjamin H Lee; Qunying Lei; Daniel J Brat; Keqiang Ye; Titus J Boggon; Chuan He; Sumin Kang; Jun Fan; Jing Chen
Journal:  Nat Cell Biol       Date:  2015-10-19       Impact factor: 28.824

4.  1-Hydroxy-8-methoxy-anthraquinon Reverses Cisplatin Resistance by Inhibiting 6PGD in Cancer Cells.

Authors:  Huamin Zhang; Haowei Zhang; Sihui Wang; Zhihai Ni; Tiejun Wang
Journal:  Open Life Sci       Date:  2019-11-15       Impact factor: 0.938

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.